Q-omics provides the consensus-scored IP6K3 profile across patient tissues and cancer cell-line models. IP6K3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IP6K3 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, IP6K3 RNA expression shows 13,900 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, THCA, and TGCT as cancer lineages where IP6K3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IP6K3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IP6K3 survival associations across molecular data types. IP6K3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IP6K3 RNA expression–survival associations across cancer types. High IP6K3 expression shows unfavorable associations in UVM, KIRP, HNSC and OV, but favorable associations in COAD and DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IP6K3 RNA expression.
This table summarizes IP6K3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for IP6K3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IP6K3 shows lower tumor expression in THCA, LUSC, COAD, KICH, STAD and LIHC. The THCA box plot shows higher IP6K3 RNA expression in normal versus tumor tissue (log2 FC = −3.782, t-test p < 0.001).
This table shows molecular features associated with IP6K3 in patient tissues and cancer cell lines. In patient samples, IP6K3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IP6K3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
